SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: RXGOLF who wrote (28183)2/13/1999 7:57:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Ligand made the "Charting the Markets" section on Monday's Barron's:

The FDA approved Ontak, the drug company's treatment for t-cell
lymphoma, a rare form of non-Hodgkin's lymphoma. Earlier, the FDA
approved Panretin gel for topical treatment of lesions from Kaposi's sarcoma.